BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,173,281 | -22.9% | 869,300 | -7.5% | 0.68% | -14.7% |
| Q2 2023 | $76,719,553 | +107820.4% | 939,846 | -1.9% | 0.80% | +4.7% |
| Q1 2023 | $71,089 | -10.3% | 958,207 | +0.2% | 0.77% | -13.2% |
| Q4 2022 | $79,218 | -99.9% | 955,821 | +299.0% | 0.88% | +9.1% |
| Q3 2022 | $68,035,000 | -9.6% | 239,542 | +10.3% | 0.81% | -4.4% |
| Q2 2022 | $75,280,000 | -22.9% | 217,241 | -3.7% | 0.85% | -9.3% |
| Q1 2022 | $97,657,000 | -14.8% | 225,521 | +1.9% | 0.93% | -11.8% |
| Q4 2021 | $114,556,000 | -48.1% | 221,376 | -51.4% | 1.06% | -0.2% |
| Q3 2021 | $220,632,000 | +107.5% | 455,466 | +93.1% | 1.06% | +2.9% |
| Q2 2021 | $106,307,000 | +15.6% | 235,907 | -2.0% | 1.03% | +13.4% |
| Q1 2021 | $91,937,000 | +10.3% | 240,736 | -8.3% | 0.91% | -2.0% |
| Q4 2020 | $83,383,000 | +34.9% | 262,402 | +5.1% | 0.93% | +10.6% |
| Q3 2020 | $61,806,000 | +1.2% | 249,555 | +7.9% | 0.84% | -18.2% |
| Q2 2020 | $61,048,000 | +28.0% | 231,232 | -8.2% | 1.03% | +5.9% |
| Q1 2020 | $47,711,000 | -16.0% | 251,795 | -2.7% | 0.97% | +10.0% |
| Q4 2019 | $56,822,000 | +3.9% | 258,732 | -7.4% | 0.88% | +3.8% |
| Q3 2019 | $54,712,000 | -3.1% | 279,284 | +3.1% | 0.85% | -0.5% |
| Q2 2019 | $56,480,000 | +3.6% | 270,994 | -1.2% | 0.85% | +0.8% |
| Q1 2019 | $54,524,000 | +41.9% | 274,317 | +3.4% | 0.85% | +27.8% |
| Q4 2018 | $38,412,000 | -31.7% | 265,423 | -3.7% | 0.66% | -20.1% |
| Q3 2018 | $56,274,000 | +4.4% | 275,705 | -24.3% | 0.83% | +1.0% |
| Q2 2018 | $53,904,000 | +14.9% | 364,339 | +17.3% | 0.82% | -24.5% |
| Q1 2018 | $46,925,000 | +4.4% | 310,682 | -10.4% | 1.09% | +9.9% |
| Q4 2017 | $44,936,000 | -18.7% | 346,865 | -24.1% | 0.99% | -23.0% |
| Q3 2017 | $55,273,000 | -14.5% | 457,217 | -16.9% | 1.28% | -15.7% |
| Q2 2017 | $64,673,000 | +11.5% | 550,410 | -3.6% | 1.52% | +8.7% |
| Q1 2017 | $58,027,000 | +0.4% | 570,853 | +1.6% | 1.40% | -3.3% |
| Q4 2016 | $57,777,000 | -12.4% | 561,872 | -6.7% | 1.45% | -14.4% |
| Q3 2016 | $65,969,000 | -3.6% | 602,454 | -0.7% | 1.69% | -6.1% |
| Q2 2016 | $68,411,000 | +1.6% | 606,644 | -14.8% | 1.80% | +8.2% |
| Q1 2016 | $67,332,000 | -1.4% | 712,358 | -6.1% | 1.67% | +1.5% |
| Q4 2015 | $68,309,000 | -3.1% | 758,992 | -0.4% | 1.64% | -4.4% |
| Q3 2015 | $70,483,000 | -6.8% | 762,305 | -0.8% | 1.72% | +1.4% |
| Q2 2015 | $75,666,000 | +0.6% | 768,416 | +2.5% | 1.69% | +0.2% |
| Q1 2015 | $75,201,000 | +10.7% | 749,834 | +2.0% | 1.69% | +10.2% |
| Q4 2014 | $67,947,000 | +0.1% | 735,359 | +1.3% | 1.53% | -2.2% |
| Q3 2014 | $67,910,000 | – | 725,922 | – | 1.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |